Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection-Reference-Cited by-同舟云学术

Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection

Published:2018-09-21 Issue:6 Volume:12 Page:523-530
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Ooka Yoshihiko^ORCID,Miho Kanda,Shuntaro Obi,Nakamura Masato,Ogasawara Sadahisa,Suzuki Eiichiro,Yasui Shin,Chiba Tetsuhiro,Arai Makoto,Kanda Tatsuo,Maruyama Hitoshi,Yokosuka Osamu,Kato Naoya,Mochizuki Hitoshi,Omata Masao

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/article/10.1007/s12072-018-9895-5/fulltext.html

Reference28 articles.

1. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15(6):645–653

2. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21(11):762–768

3. Reddy KR, Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62(1):79–86

4. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016;63(4):1112–1119

5. Hosoda K, Yokosuka O, Kato N, Ito Y, Ohto M, Omata M. Long-term effects of alpha-interferon for treatment of chronic hepatitis C in terms of histological changes with aminotransferase normalization and hepatitis C virus RNA seroconversion. Gastroenterol Jpn 1993;28(Suppl 5):115–117

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study;Hepatology Research;2023-09-19

2. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals;Scientific Reports;2023-06-02

3. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals;2023-02-28

4. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals;Viruses;2023-01-13

5. Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR;Viruses;2022-10-31